Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma. [PDF]
Clin Transl SciTachibana M +16 more
europepmc +1 more source
Effects of Diazepam Addition to Standard Treatment of Atrial Fibrillation in Emergency Department Settings: A Unicentric Retrospective Study. [PDF]
Medicina (Kaunas)Vidović K, Krnić J, Benzon B.
europepmc +1 more source
Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model. [PDF]
PharmaceuticsGu W, Shao Q, Jiang L.
europepmc +1 more source
Development and validation of a prognostic model and scoring system for in-hospital mortality risk in neonates with heart failure within 28 days: a multicenter retrospective case-control study. [PDF]
Sci RepWei M +8 more
europepmc +1 more source
De novo design of protein competitors for small molecule immunosensing
de Stigter Y, Godschalk T, Merkx M.
europepmc +1 more source
Related searches:
After 200 years of use, digitalis still appears to have a place in our armamentarium for heart failure and atrial fibrillation despite the proven survival benefits with ACE inhibitors and beta-blockers. Digoxin therapy is inexpensive and well tolerated and may result in considerable savings.
Eric J, Eichhorn, Mihai, Gheorghiade
openaire +2 more sources
Anti‐Digoxin Antibody in Digoxin Intoxication
Australian and New Zealand Journal of Medicine, 1981Abstract: This study was conducted to investigate the action of anti‐digoxin antibody in digoxin intoxication. Anti‐digoxin antibody was raised in sheep and administered to six dogs following intravenous infusion of digoxin (0.04 or 0.16mg/kg body weight), either as whole serum or as partially purified gamma globulin. Plasma and urine digoxin levels,
D, Anderson, R, Penny, M F, O'Rourke
openaire +2 more sources
A variable or poor response to a therapeutic agent may not have its origin in the patient; it may be due to a formulation defect in the drug product administered. The most commonly recognized formulation defect in a dosage form such as a tablet is a deficiency or excess of the active ingredient.
T G, Vitti, D, Banes, T E, Byers
openaire +2 more sources
Serum digoxin and metabolites were assayed in plasma and urine by HPLC in 10 dialysis-dependent patients with end-stage renal failure (group I) and in five patients with comparatively normal renal function (group II) after ingestion of 150 muCi 3H-digoxin-12 alpha.
M H, Gault +6 more
openaire +2 more sources